# Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

> **NCT05049902** · PHASE4 · COMPLETED · sponsor: **Shandong University** · enrollment: 1300 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Amoxicillin
- **DRUG:** Clarithromycin
- **DRUG:** Tetracycline
- **DRUG:** Metronidazole
- **DRUG:** Bismuth Potassium Citrate
- **DRUG:** Colloidal Bismuth Pectin
- **DRUG:** Vonoprazan fumarate

## Key facts

- **NCT ID:** NCT05049902
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-21
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 1300 (ACTUAL)
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05049902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05049902, "Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05049902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*